In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Symphony financing to support OxiGene cancer, eye programs

Executive Summary

Private equity group Symphony Capital Partners has created and agreed to invest up to $25mm in Symphony Vida, an off-balance sheet entity that will take on the development risk of biotech OxiGene's ophthalmic program. As part of the deal, Symphony Capital may elect two members to OxiGene's board.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement
    • Special-Purpose Financing Vehicle

Related Companies